Loading data for GRCE — first visit, this takes a few seconds.
Grace Therapeutics Inc. (GRCE)
NasdaqCM: GRCE
· Real-Time Price · USD
2.20
+0.06 (2.80%)
At close: Aug 24, 2026, 5:20 PM
The price, the headline numbers and the latest news, in one place.
Grace Therapeutics Inc. (GRCE) Stock Price, Analysis & Data
2.80% (1D)
No data available
| Bid | 1.56 |
| Market Cap | 45.73M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -20.22M |
| 0.43 | |
| -1.17 | |
| n/a | |
| -4.68 | |
| P/B (ttm) | 0.73 |
| P/S (ttm) | n/a |
| Earnings Date | Jun 20, 2025 |
| Ask | 2.76 |
| Volume | 75,899 |
| Avg. Volume (20D) | 250,259 |
| Open | 2.15 |
| Previous Close | 2.14 |
| Day's Range | 2.15 - 2.23 |
| 52-Week Range | 1.79 - 5.18 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About GRCE
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-form...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 7, 2012
Employees 5
Stock Exchange NasdaqCM
Ticker Symbol GRCE
Website https://www.gracetx.com
Financial Performance
In 2026, Grace Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -7.79M, a decrease of -18.55%.
Financial StatementsEarnings Surprise
Grace Therapeutics has released their quarterly earnings on Aug 13, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.18 misses estimates by 0.00, with 37.93% YoY growth.
Grace Therapeutics Inc. is scheduled to release its earnings on Jun 20, 2025, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
